Total Returns (Price + Dividend) 
Company does not have enough history
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.34%
EBIT Growth (5y)
18.74%
EBIT to Interest (avg)
7.09
Debt to EBITDA (avg)
1.36
Net Debt to Equity (avg)
0.55
Sales to Capital Employed (avg)
0.61
Tax Ratio
23.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.02%
ROE (avg)
8.88%
Valuation key factors
Factor
Value
P/E Ratio
59
Industry P/E
Price to Book Value
5.83
EV to EBIT
51.07
EV to EBITDA
26.19
EV to Capital Employed
4.11
EV to Sales
6.33
PEG Ratio
NA
Dividend Yield
32.32%
ROCE (Latest)
8.05%
ROE (Latest)
9.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot : Dec 2021
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 544 Foreign Institutions (50.17%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Jun'23
Jun'23
Jun'22
Change(%)
Net Sales
761.50
681.80
11.69%
Operating Profit (PBDIT) excl Other Income
183.80
189.90
-3.21%
Interest
23.10
8.80
162.50%
Exceptional Items
-105.40
-19.50
-440.51%
Consolidate Net Profit
-27.90
58.20
-147.94%
Operating Profit Margin (Excl OI)
123.60%
148.90%
-2.53%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2023 is 11.69% vs 12.14% in Jun 2022
Consolidated Net Profit
YoY Growth in year ended Jun 2023 is -147.94% vs 4.86% in Jun 2022
About Dechra Pharmaceuticals Plc 
Dechra Pharmaceuticals Plc
Pharmaceuticals: Major
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine, Food producing Animal Products and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal, Equine and Food Producing Animal Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos, Zycortal and Vetoryl.
Company Coordinates 
Company Details
Lostock Gralam , NORTHWICH None : CW9 7UA
Registrar Details






